Business
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
MOUNTAIN VIEW, Calif., February 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from th
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/a3d2a13ed2b372da30325be28e4bd1fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KtaVYVOGt4yANRxjHiurSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a3d2a13ed2b372da30325be28e4bd1fb","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/M5tZ6PTWuJQE6BGKJ_JEAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a3d2a13ed2b372da30325be28e4bd1fb","width":1200,"height":388}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., February 13, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the Phase 2 proof-of-concept study are expected following completion of dosing and data analysis and are anticipated to guide future development decisions for ALTO-101.","length":693,"tagName":"p"},{"type":"text","content":"Cognitive impairment represents a core, persistent feature of schizophrenia affecting nearly all patients and is a major driver of long-term functional disability, for which there are currently no approved pharmacologic treatments.","length":231,"tagName":"p"},{"type":"text","content":"Alto met its enrollment goal for the Phase 2 proof-of-concept trial (NCT06502964) with 83 CIAS patients enrolled across 13 clinical sites in the United States. The randomized, double-blind, placebo-controlled crossover study is designed to assess the effects of ALTO-101 on electroencephalography (EEG) measures that have been consistently linked to cognitive dysfunction in schizophrenia. Participants in the study receive 10 days of treatment with ALTO-101 or placebo, followed by a washout period, and then 10 days of treatment with the opposite intervention than was received in the fir...